Humanin

What is humanin?

Humanin is a short peptide encoded within mitochondrial DNA and studied for cell-protective and metabolic signaling roles. It was identified when researchers searching for factors that block neuronal death found a peptide that shielded cells from a range of Alzheimer-related insults (Hashimoto et al., 2001, PNAS, PMID 11371646). Because it is transcribed from the mitochondrial genome rather than the nuclear genome, it belongs to a small class called mitochondrial-derived peptides (MDPs), which also includes MOTS-c (Lee et al., 2015, Cell Metab, PMID 25738459).

The practical takeaway: humanin is a signaling molecule that laboratory work links to stress resistance. It is not an approved therapy, and the strongest evidence sits in cells and animals rather than controlled human trials.

How does humanin work?

Humanin appears to act as a cytoprotective signal that helps cells resist stress-induced death. In the founding cell studies, humanin blunted neuronal death triggered by several familial Alzheimer disease genes and by amyloid-beta exposure (Hashimoto et al., 2001, PNAS, PMID 11371646). Later work has grouped humanin with a broader stress-response and metabolic-signaling role shared across MDPs, though this remains an area of active research.

Its sibling peptide MOTS-c is tied to activation of AMPK, a central energy-sensing pathway, and to metabolic homeostasis under stress in animal models (Lee et al., 2015, Cell Metab, PMID 25738459). Humanin and MOTS-c are studied as related but distinct signals, so findings for one do not automatically transfer to the other.

Beyond neurons, humanin has also been studied in metabolism. In animal work, delivering humanin to the brain improved whole-body insulin sensitivity, and the same research noted that circulating humanin declines with age in humans (Muzumdar et al., 2009, PLoS ONE, PMID 19623253).

Important limit: mechanism described in cells and rodents does not confirm the same effect in people. Human data on humanin is largely observational, meaning researchers have measured circulating levels rather than tested a given dose against a placebo (Muzumdar et al., 2009, PMID 19623253).

What does the research report on humanin dosing?

There is no established human dosing for humanin, and no completed human trial has defined a research-reported human dose range for it.

Because the published record is preclinical, dosing in the literature refers to cell-culture concentrations and animal-model injections, which do not translate to a human protocol. This is different from compounds where named human trials have published participant dose ranges. For humanin, that human trial layer does not yet exist.

If you are weighing any mitochondrial peptide, the dose question is a clinical one. Route it to a qualified clinician who can review your full history rather than to a generic protocol.

What are the reported side effects of humanin?

Humanin does not have a defined human safety profile, because it has not gone through the controlled human trials that generate one.

Safety information in the literature is drawn from cell and animal work, which cannot rule out adverse effects in people or describe dose-dependent risks the way a human trial would. This is the current state of the evidence: the absence of reported human side effects reflects the absence of human trials, not a demonstration of safety. Anyone considering research use should treat the safety picture as unknown and discuss it with a clinician.

How does humanin compare to MOTS-c and SS-31?

Humanin and MOTS-c are both mitochondrial-derived peptides, while SS-31 is a separate synthetic mitochondrial-targeted peptide, and all three have thin human data.

Humanin and MOTS-c are encoded within mitochondrial DNA and studied as endogenous stress and metabolic signals (Hashimoto et al., 2001; Lee et al., 2015). MOTS-c research centers on AMPK and metabolic homeostasis in animal models (Lee et al., 2015, Cell Metab, PMID 25738459), while humanin research began with cytoprotection in neuronal cell models (Hashimoto et al., 2001, PNAS, PMID 11371646). SS-31 is not a mitochondrial-derived peptide at all; it is described as a synthetic compound designed to localize to mitochondria, and its human evidence remains investigational and limited. For a fuller side-by-side, see the linked MOTS-c and SS-31 pages.